Risk factors for unfavorable outcome and impact of early post-transplant infection in solid organ recipients with COVID-19 : A prospective multicenter cohort study

The aim was to analyze the characteristics and predictors of unfavorable outcomes in solid organ transplant recipients (SOTRs) with COVID-19. We conducted a prospective observational cohort study of 210 consecutive SOTRs hospitalized with COVID-19 in 12 Spanish centers from 21 February to 6 May 2020. Data pertaining to demographics, chronic underlying diseases, transplantation features, clinical, therapeutics, and complications were collected. The primary endpoint was a composite of intensive care unit (ICU) admission and/or death. Logistic regression analyses were performed to identify the factors associated with these unfavorable outcomes. Males accounted for 148 (70.5%) patients, the median age was 63 years, and 189 (90.0%) patients had pneumonia. Common symptoms were fever, cough, gastrointestinal disturbances, and dyspnea. The most used antiviral or host-targeted therapies included hydroxychloroquine 193/200 (96.5%), lopinavir/ritonavir 91/200 (45.5%), and tocilizumab 49/200 (24.5%). Thirty-seven (17.6%) patients required ICU admission, 12 (5.7%) suffered graft dysfunction, and 45 (21.4%) died. A shorter interval between transplantation and COVID-19 diagnosis had a negative impact on clinical prognosis. Four baseline features were identified as independent predictors of intensive care need or death: advanced age, high respiratory rate, lymphopenia, and elevated level of lactate dehydrogenase. In summary, this study presents comprehensive information on characteristics and complications of COVID-19 in hospitalized SOTRs and provides indicators available upon hospital admission for the identification of SOTRs at risk of critical disease or death, underlining the need for stringent preventative measures in the early post-transplant period.

Medienart:

E-Artikel

Erscheinungsjahr:

2021

Erschienen:

2021

Enthalten in:

Zur Gesamtaufnahme - volume:16

Enthalten in:

PloS one - 16(2021), 4 vom: 30., Seite e0250796

Sprache:

Englisch

Beteiligte Personen:

Salto-Alejandre, Sonsoles [VerfasserIn]
Jiménez-Jorge, Silvia [VerfasserIn]
Sabé, Nuria [VerfasserIn]
Ramos-Martínez, Antonio [VerfasserIn]
Linares, Laura [VerfasserIn]
Valerio, Maricela [VerfasserIn]
Martín-Dávila, Pilar [VerfasserIn]
Fernández-Ruiz, Mario [VerfasserIn]
Fariñas, María Carmen [VerfasserIn]
Blanes-Juliá, Marino [VerfasserIn]
Vidal, Elisa [VerfasserIn]
Palacios-Baena, Zaira R [VerfasserIn]
Hernández-Gallego, Román [VerfasserIn]
Carratalá, Jordi [VerfasserIn]
Calderón-Parra, Jorge [VerfasserIn]
Ángeles Marcos, María [VerfasserIn]
Muñoz, Patricia [VerfasserIn]
Fortún-Abete, Jesús [VerfasserIn]
Aguado, José María [VerfasserIn]
Arnaiz-Revillas, Francisco [VerfasserIn]
Blanes-Hernández, Rosa [VerfasserIn]
de la Torre-Cisneros, Julián [VerfasserIn]
López-Cortés, Luis E [VerfasserIn]
García de Vinuesa-Calvo, Elena [VerfasserIn]
Rosso, Clara M [VerfasserIn]
Pachón, Jerónimo [VerfasserIn]
Sánchez-Céspedes, Javier [VerfasserIn]
Cordero, Elisa [VerfasserIn]
COVIDSOT Working Team [VerfasserIn]

Links:

Volltext

Themen:

Immunosuppressive Agents
Journal Article
Multicenter Study
Observational Study
Research Support, Non-U.S. Gov't

Anmerkungen:

Date Completed 12.05.2021

Date Revised 11.11.2023

published: Electronic-eCollection

Citation Status MEDLINE

doi:

10.1371/journal.pone.0250796

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM324680562